Making statistical sense of the Molnupiravir MOVe-OUT clinical trial was written by Thorlund, Kristian;Sheldrick, Kyle;Meyerowitz-Katz, Gideon;Singh, Sonal;Hill, Andrew. And the article was included in American Journal of Tropical Medicine and Hygiene in 2022.Recommanded Product: ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate The following contents are mentioned in the article:
A review. Oral therapies for the early treatment of COVID-19 may prevent disease progression and health system overcrowding. A new oral therapeutic named molnupiravir has been promoted as providing an approx. 50% reduction in death or the need for hospitalization. The clin. trial evaluating this drug was stopped early at the recommendation of the Data Safety and Monitoring Board after approx. 50% of the sample had been recruited. At the point of discontinuing the trial, approx. 90% of the planned sample had been recruited and had available follow-up data accessible. We discuss issues about the study conduct, anal., and interpretation, including (1) the authors and sponsors presented the interim anal. as the primary anal.; (2) communication between sponsors and the Data Safety and Monitoring Board was insufficient; (3) the treatment effects reverse when examining only the post-interim anal. population, and are substantially attenuated when examining the full data; (4) the choice of primary anal. is incorrect; (5) anal. of lost-to-follow-up patients favors the study drug; and (6) other known molnupiravir trials were not presented in the primary study findings. As a result of methodol. and statistical concerns, it seems that external trials, sep. from those supported by the sponsoring company, are required to determine the utility of this drug. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Recommanded Product: ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofurans and furans are important oxygen-containing heterocycles that often exhibit interesting properties for biological applications or applications in the cosmetic industry. Commercial tetrahydrofuran contains substantial water that must be removed for sensitive operations, e.g. those involving organometallic compounds. Although tetrahydrofuran is traditionally dried by distillation from an aggressive desiccant, molecular sieves are superior.Recommanded Product: ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem